ValuEngine lowered shares of CHF Solutions (NASDAQ:CHFS) from a buy rating to a hold rating in a research note released on Thursday.
Several other equities analysts also recently commented on the stock. Dawson James initiated coverage on shares of CHF Solutions in a research report on Tuesday, August 28th. They set a buy rating and a $3.30 target price on the stock. Zacks Investment Research raised shares of CHF Solutions from a sell rating to a buy rating and set a $1.75 target price on the stock in a research report on Tuesday, July 24th.
Shares of NASDAQ CHFS traded up $0.03 during mid-day trading on Thursday, reaching $1.03. The company had a trading volume of 30,157 shares, compared to its average volume of 123,204. CHF Solutions has a twelve month low of $0.77 and a twelve month high of $24.45. The company has a market capitalization of $7.07 million, a PE ratio of -0.03 and a beta of 2.19.
CHF Solutions (NASDAQ:CHFS) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.01). CHF Solutions had a negative return on equity of 166.88% and a negative net margin of 471.94%. The company had revenue of $1.10 million during the quarter. Analysts anticipate that CHF Solutions will post -2.9 EPS for the current fiscal year.
A hedge fund recently bought a new stake in CHF Solutions stock. Dimensional Fund Advisors LP bought a new position in shares of CHF Solutions Inc (NASDAQ:CHFS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 87,453 shares of the company’s stock, valued at approximately $161,000. Dimensional Fund Advisors LP owned about 1.30% of CHF Solutions at the end of the most recent reporting period. 19.95% of the stock is owned by institutional investors.
About CHF Solutions
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. The company focuses on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
See Also: Return on Investment (ROI)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.